#1 - Gilead Sciences (NASDAQ:GILD)
The biotechnology sector is not the first sector many investors would think of when considering cheap dividend stocks. Many of these companies put their cash back into drug discovery. That's why Gilead Sciences Inc. (NASDAQ: GILD) stands out.
The company is a giant in the pharmaceutical industry with commercially available treatments for HIV, hepatitis, cancer, and other diseases. It also has an expansive pipeline of 55 candidates as of this writing. Among the candidates in clinical trials are several cell therapies the company picked up with its acquisition of Kite Pharma in 2017. Gilead has plans to get at least 10 of these candidates into the market by 2030.
That explains why the stock may move higher, and here's why it’s a good buy. As of April 4, 2024, GILD stock is trading near its 52-week low at $70.30. Plus, it has an attractive dividend with a yield of 4.38%. The dividend has been growing for nine consecutive years.
About Gilead Sciences
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Read More - Current Price
- $92.57
- Consensus Rating
- Moderate Buy
- Ratings Breakdown
- 15 Buy Ratings, 12 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $96.43 (4.2% Upside)
